PALO ALTO, Calif., March 4, 2013 /PRNewswire/ -- CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, announced that clinical data from studies of Corus® CAD, the only clinically validated gene expression test for obstructive coronary artery disease (CAD), will be presented at the American College of Cardiology 62nd Annual Scientific Session taking place March 9-11, 2013 at the Moscone Center in San Francisco, CA.
John A. McPherson, MD, FACC, FACP, Associate Professor of Medicine, Vanderbilt University School of Medicine, will present "Improved Diagnostic Work-up of Patients Presenting to the Cardiologist with Symptoms of Suspected Obstructive Coronary Artery Disease: Gender Specific Results from the IMPACT Trial." Dr. McPherson's presentation will feature results from the IMPACT Trial demonstrating the clinical utility of Corus CAD and its impact on the diagnostic pathway for evaluating women with symptoms suggestive of obstructive CAD in the cardiologist's office.
- Presentation Date and Time: Saturday, March 9, 2013 from 3:45-4:30 PM
- Poster Number: 1154-73
- Location: Poster Sessions, Expo North
Szilard Voros, MD, FACC, FSCCT, FAHA, Associate Professor of Medicine/Cardiology and Radiology at Stony Brook University will present "A Previously Validated Peripheral Blood Gene Expression Score Is Primarily Influenced by Plaque Burden, Rather than Ischemia, in 371 Patients from the COMPASS Multi-Center Study." Dr. Voros's presentation will focus on the role of plaque presence, rather than ischemia, as the main driver of gene expression scores.
- Presentation Date and Time: Sunday, March 10, 2013 from 3:45-4:30 PM
- Poster Number: 1269-340
- Location: Poster Sessions, Expo North
Additionally, CardioDx will host an educational symposium—"Current Challenges and Emerging Solutions to CAD Diagnosis in the New Era of Patient Management"— by registration only. The symposium will be chaired by Dr. Pamela Douglas, MACC, Ursula Geller Professor of Research in Cardiovascular Diseases, Duke Clinical Research Institute and former president of the American College of Cardiology. The program will feature U.S. clinical trial data and patient case presentations by Dr. William E. Boden, FACC, FAHA, Professor of Medicine, Albany Medical College; Dr. Alexandra Lansky, FESC, FACC, Associate Professor, Cardiovascular Medicine, Yale University School of Medicine; and Dr. Gregory Thomas, MPH, FACC, FASNC, Medical Director, MemorialCare Heart and Vascular Institute, Long Beach Memorial Medical Center. To pre-register for the event, please visit www.cardiodxsymposium.com.
- Symposium Date and Time: Sunday, March 10th, from 7:00-8:30 PM
- Location: W Hotel San Francisco
CardioDx recently announced the publication of the COMPASS (Coronary Obstruction Detection by Molecular Personalized Gene Expression) study in Circulation: Cardiovascular Genetics, a journal of the American Heart Association. Results of this prospective, multi-center U.S. study showed that Corus CAD outperformed traditional stress testing with myocardial perfusion imaging (MPI), demonstrating high accuracy with both a higher sensitivity (89 percent vs. 27 percent, p<0.001) and higher negative predictive value (96 percent vs. 88 percent, p<0.001) than MPI for assessing obstructive CAD.
With a simple blood draw, Corus CAD can safely, accurately and conveniently help primary care clinicians and cardiologists assess whether or not a stable non-diabetic patient's symptoms are due to obstructive CAD, enabling many patients to avoid unnecessary noninvasive and invasive cardiac procedures and exposure to imaging-related radiation risks or imaging agent intolerance. Corus CAD is the only sex-specific test for obstructive CAD, accounting for critical biological differences between men and women. Corus CAD has been used commercially by clinicians in more than 35,000 patients and is a covered benefit for more than 40 million Medicare enrollees in the U.S.
Corus CAD has been recognized by The Wall Street Journal's Technology Innovation Awards, honored as a Gold Edison Award recipient, and named one of TIME's Top Ten Medical Breakthroughs. CardioDx was recently honored as one of FierceMedicalDevices' "Fierce 15" most promising privately-held medical device and diagnostic companies.
CardioDx, Inc., a pioneer in the field of cardiovascular genomic diagnostics, is committed to developing clinically validated tests that empower clinicians to better tailor care to each individual patient. Strategically focused on coronary artery disease, cardiac arrhythmia and heart failure, CardioDx is poised to expand patient access and improve healthcare quality and efficiency through the commercialization of genomic technologies. For more information, please visit www.cardiodx.com.
SOURCE CardioDx, Inc.